bell
The current prices are delayed by 15 mins, login to check live prices.
Marksans Pharma Ltd share price logo

Marksans Pharma Ltd

(MARKSANS)

₹310.53.8%

as on 04:01PM, 12 Dec 2024

Overview
News
Financials
Q2 2024 Results
Technicals

Marksans Pharma Ltd Analyst Rating

based on 3 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 3 analysts offering long term price targets for Marksans Pharma Ltd. An average target of ₹330.33

Source: S&P Global Market Intelligence

Marksans Pharma Ltd Share analysis

Marksans Pharma Ltd price forecast by 3 analysts

Upside of2.35%

High

₹376

Target

₹330.33

Low

₹265

Marksans Pharma Ltd target price ₹330.33, a slight upside of 2.35% compared to current price of ₹310.5. According to 3 analysts rating.

Source: S&P Global Market Intelligence

Marksans Pharma Ltd Performance

  • Day's Low

    Day's High

    ₹309
    ₹324.5
  • 52 Week's Low

    52 Week's High

    ₹130
    ₹358.7
1 Month Return+ 7.4 %
3 Month Return+ 20.41 %
1 Year Return+ 103.31 %
Previous Close₹322.75
Open₹324.50
Volume13.36L
Upper Circuit-
Lower Circuit-
Market Cap₹14,625.86Cr

Marksans Pharma Ltd Key Statistics

P/E Ratio42.13
PEG Ratio54.72
Market Cap₹14,625.86 Cr
P/B Ratio5.62
EPS6.95
Dividend Yield0.4
SectorPharmaceuticals
ROE11.46

Marksans Pharma Ltd Peer Comparison

Company
Analyst ViewMarket Cap5 Year CAGRDebt to Asset RatioNet ProfitYearly Revenue
BUY₹14,625.86 Cr446.06%0.51₹314 Cr₹2,177 Cr
NA₹302.38 Cr124.07%0.66₹5 Cr₹155 Cr
NA₹30.65 Cr152.18%0.50NANA
NA₹302.57 Cr463.22%0.53NANA
NA₹255.74 Cr146.51%0.52₹16 Cr₹108 Cr

About Marksans Pharma Ltd

Marksans Pharma Limited is a public limited company that specializes in research, manufacture, marketing and sale of pharmaceutical formulations. Established in April 1982, the Company has its research and development centers located in Verna Goa and Navi Mumbai. On 30th March 2015, they issued and allotted 24006494 equity shares of ₹1 each to qualified institutional buyers for ₹54.67 per share under QIP. On 7th February 2015, the Company decided to redeem 1350000 cumulative redeemable preference shares of face value ₹100 each out of profits in tranches before due date of redemption, which was decided to be 27th March 2018. 50000 Bonds of USD 1000 value each were issued during the financial year 2015, out of which 49939 Bonds were bought and extinguished by the Company. 150000 preference shares of ₹100 each were redeemed at par in 2017 and the issued, subscribed and paidup preference share capital was reduced to 1100000 of ₹100 each. Marksans Pharma Limited is a long-standing public limited company offering research, manufacture, marketing and sale of pharmaceutical formulations.

Share Price: ₹310.50 per share as on 12 Dec, 2024 04:01 PM
Market Capitalisation: ₹14,625.86Cr as of today
Revenue: ₹641.92Cr as on September 2024 (Q3 24)
Net Profit: ₹97.76Cr as on September 2024 (Q3 24)
Listing date: 21 Jan, 2002
Chairperson Name: Mark Saldanha
OrganisationMarksans Pharma Ltd
HeadquartersMumbai
IndustryPharmaceuticals
E-voting on sharesClick here to vote

Key events for Marksans Pharma Ltd

  • Marksans Pharma Hits 52-Week High After FDA Approval - 27 Nov, 2024

    Marksans Pharma shares surged 4.1% to a 52-week high of ₹351.5, marking a 142% gain over the past year. The rally follows FDA approval for Loratadine Tablets, used for treating allergies. The company also reported a 16% increase in net profit and a 21% rise in revenue for Q2FY25.
  • Marksans Pharma Hits New High on Strong Q2 Results - 26 Nov, 2024

    Marksans Pharma's stock surged 30% in a month, reaching a record high of Rs 343.85, driven by strong Q2 results with a 20.8% revenue growth and 16.6% profit increase. The company received USFDA approval for Loratadine Tablets, further boosting its outlook.
  • Marksans Pharma Secures USFDA Approval for Allergy Drug - 22 Nov, 2024

    Marksans Pharma Ltd has received final USFDA approval for its Loratadine tablets, enhancing its portfolio in allergy treatments. The stock rose 3.2% following the announcement.
  • Marksans Pharma Reports Strong Q3 Growth - 13 Nov, 2024

    Marksans Pharma's standalone net sales for September 2024 reached Rs 308.63 crore, up 50.79% YoY. Net profit surged 102% to Rs 63.20 crore, with EBITDA rising 57.11%. The stock has delivered impressive returns of 92.63% over the last six months and 118.07% over the past year.
  • Marksans Pharma Reports Strong Q2 FY25 Financials - 12 Nov, 2024

    Marksans Pharma's Q2 FY25 results show significant growth, with revenue rising 20.84% YoY to Rs 641.92 crore and net profit increasing 16.56% YoY. The stock gained 2.70% following the announcement, reflecting positive investor sentiment.

Insights on Marksans Pharma Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    FII Holding Up

    img

    Foreign Institutions have increased holdings from 7.71% to 10.43% in Sep 2024 quarter

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, MARKSANS has outperformed top 5 stocks with highest market-cap in Pharmaceuticals

  • imgPOSITIVE IMPACT

    MF Holding Up

    img

    Mutual Funds have increased holdings from 2.82% to 3.02% in Sep 2024 quarter

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, MARKSANS has outperformed top 5 stocks with highest market-cap in Pharmaceuticals

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 3 quarters, 78.29 Cr → 96.72 Cr (in ₹), with an average increase of 10.0% per quarter

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 3 quarters, 576.54 Cr → 652.98 Cr (in ₹), with an average increase of 6.0% per quarter

  • imgNO EFFECT

    Promoter Holding Unchanged

    img

    Promoters holdings remained unchanged at 43.87% of holdings in Sep 2024 quarter

  • imgNEGATIVE IMPACT

    Retail Holding Down

    img

    Retail Investor have decreased holdings from 33.78% to 30.71% in Sep 2024 quarter

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 7 days, MARKSANS stock has moved down by -7.4%

Marksans Pharma Ltd Financials

Value in ₹ crore
DetailsQ'3 23Q'4 23Q'1 24Q'2 24Q'3 24
Revenue₹531.24Cr (-)₹586.13Cr (↑10.33%)₹560.01Cr (↓4.46%)₹590.62Cr (↑5.47%)₹641.92Cr (↑8.69%)
Net Income₹83.85Cr (-)₹82.97Cr (↓1.05%)₹77.64Cr (↓6.42%)₹89.07Cr (↑14.72%)₹97.76Cr (↑9.76%)
Net Profit Margin15.78% (-)14.16% (↓10.27%)13.86% (↓2.12%)15.08% (↑8.80%)15.23% (↑0.99%)
Value in ₹ crore
Details2021202220232024
Total Assets₹741.13Cr (-)₹966.49Cr (↑30.41%)₹1,346.73Cr (↑39.34%)₹1,518.05Cr (↑12.72%)
Total Liabilities₹141.41Cr (-)₹181.82Cr (↑28.58%)₹235.40Cr (↑29.47%)₹295.34Cr (↑25.46%)
Value in ₹ crore
Details20202021202220232024
Operating Cash Flow₹107.58Cr (-)₹106.92Cr (↓0.61%)₹55.97Cr (↓47.65%)₹51.73Cr (↓7.58%)₹34.05Cr (↓34.18%)

Index Inclusions

BSE Healthcare

₹44,176.87

-0.58 (-256.19%)

BSE Small-Cap

₹57,125.14

-1 (-578.34%)

S&P BSE AllCap

₹10,471.31

0.68 (71.07%)

Marksans Pharma Ltd Shareholding Pattern

InvestorsHoldings %FY Quarter3M change
Promoter Holdings
43.87%
0.00
Foreign Institutions
10.43%
35.16
Mutual Funds
3.02%
7.44
Retail Investors
30.71%
-9.08
Others
11.96%
1.24

Marksans Pharma Ltd Key Indicators

Details20202021202220232024
Return On Equity %7.0717.2915.0210.8511.46
Details20202021202220232024
Return On Assets %20.131.8419.119.7720.66
Details20202021202220232024
Book Value Per Share (₹)15.5421.6627.138.5145.57
Details20202021202220232024
Earning Per Share (₹)2.955.834.565.856.95

Marksans Pharma Ltd Valuation

Marksans Pharma Ltd in the last 5 years

  • Overview

  • Trends

Lowest (4.67x)

April 1, 2020

Today (42.13x)

December 11, 2024

Industry (56.82x)

December 11, 2024

Highest (46.60x)

January 24, 2018

LowHigh

Marksans Pharma Ltd Earnings and Dividends

  • Marksans Pharma Ltd Earnings Results

    Marksans Pharma Ltd’s net profit jumped 15.8% since last year same period to ₹96.72Cr in the Q2 2024-2025. On a quarterly growth basis, Marksans Pharma Ltd has generated 8.98% jump in its net profits since last 3-months.

    Read More about Earnings Results
  • Marksans Pharma Ltd Dividends May,2024

    In the quarter ending March 2024, Marksans Pharma Ltd has declared dividend of ₹0.60 - translating a dividend yield of 0.34%.

    Read More about Dividends

Marksans Pharma Ltd Technicals Summary

Bearish

Neutral

Bullish

Bearish

Marksans Pharma Ltd is currently in a Bearish trading position according to technical analysis indicators.

FAQs on Marksans Pharma Ltd

  • Get a PAN card.
  • Open a Demat account.
  • Open a Trading account.
  • Link your Demat account to your Trading account.
  • Fund your Trading account.
  • Place an order to buy Marksans Pharma Ltd shares.

Marksans Pharma Ltd (MARKSANS) share price today is ₹310.5

Marksans Pharma Ltd is listed on NSE

Marksans Pharma Ltd is listed on BSE

  • Today’s highest price of Marksans Pharma Ltd is ₹324.5.
  • Today’s lowest price of Marksans Pharma Ltd is ₹309.

PE Ratio of Marksans Pharma Ltd is 42.13

PE ratio = Marksans Pharma Ltd Market price per share / Marksans Pharma Ltd Earnings per share

Today’s traded volume of Marksans Pharma Ltd(MARKSANS) is 13.36L.

Today’s market capitalisation of Marksans Pharma Ltd(MARKSANS) is ₹14625.86Cr.

Marksans Pharma Ltd(MARKSANSPrice
52 Week High
₹358.7
52 Week Low
₹130

Marksans Pharma Ltd(MARKSANS) share price is ₹310.5. It is down -13.44% from its 52 Week High price of ₹358.7

Marksans Pharma Ltd(MARKSANS) share price is ₹310.5. It is up 138.85% from its 52 Week Low price of ₹130

Marksans Pharma Ltd(MARKSANSReturns
1 Day Returns
-12.25%
1 Month Returns
7.4%
3 Month Returns
20.41%
1 Year Returns
103.31%